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Abstract Complex hereditary spastic paraplegia (HSP) is
a clinically heterogeneous group of disorders usually
inherited in an autosomal recessive manner. In the past,
complex recessive spastic paraplegias have been frequently
associated with SPG11 mutations but also with defects in
SPG15, SPG7 and a handful of other rare genes. Pleiotropy
exists in HSP genes, exemplified in the recent association
of SPG11 mutations with CMT2. In this study, we per-
formed whole exome sequence analysis and identified two
siblings with novel compound heterozygous frameshift
SPG11 mutations. The mutations segregated with disease
were not present in control databases and analysis of skin
fibroblast derived mRNA indicated that the SPG11 trun-
cated mRNA species were not degraded significantly by
non-sense mediated mRNA decay. These siblings had
severe early-onset spastic paraplegia but later in their
disease developed severe axonal neuropathy, neuropathic
pain and blue/black foot discolouration likely caused by a
combination of the severe neuropathy with autonomic
dysfunction and peripheral oedema. We also identified a
similar late-onset axonal neuropathy in a Cypriot SPG11
family. Although neuropathy is occasionally present in
SPG11, in our SPG11 patients reported here it was par-
ticularly severe, highlighting the association of axonal
neuropathy with SPG11 and the late manifestation of
axonal peripheral nerve damage.
Keywords Axonal neuropathy  Spatacsin  CMT2 
Gene  Genetics  SPG11
Introduction
The hereditary spastic paraplegias (HSPs) are heteroge-
neous inherited neurological disorders, resulting in pro-
gressive spasticity of the limbs, bladder dysfunction and
walking difficulties. Other features such as weakness,
ataxia, cognitive decline and peripheral neuropathy are
present in complex HSP. They are classified genetically as
autosomal dominant, autosomal recessive and X-linked
HSP; and clinically as pure or complicated HSP, based
upon the absence (pure) or presence (complex) of addi-
tional clinical features. To date, more than 70 different
disease-loci and more than 50 spastic paraplegia genes
(SPGs) have been identified [1, 2]. Autosomal recessive
HSP with a thin corpus callosum is a common subtype of
complex HSP. Mutations in SPG11 (encoding for Spas-
tacsin), comprise about 70 % of these cases [2–4] and the
onset is usually in the teenage years [5–12].
In the past, axonal neuropathy has been infrequently
associated with complex HSP and SPG11 mutations,
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although this is usually mild [4, 13]. Recently mutations in
SPG11 have been shown to cause Charcot–Marie–Tooth
disease type 2 (CMT2) as a distinct clinical phenotype
[14]. Spatacsin is expressed ubiquitously in the nervous
system [1] and the sural nerve biopsy pathology in typical
SPG11 cases showed a loss of unmyelinated nerve fibers
and accumulation of intra-axonal pleomorphic membra-
nous material. In CMT2 cases sural nerve biopsies showed
similar intra-axonal inclusions but also predominantly loss
of large myelinated fibers, mainly in fibers of large caliber,
in line with the diagnosis of CMT2 [14]. Although the role
of the protein is unknown, it seems to be important to the
survival of neurons [15].
In this paper we describe novel frameshift mutations in
SPG11, identified by whole exome sequencing, segregating
with the disease and investigated in mRNA. The causative
mutations were found in two sisters with complex HSP
consistent with SPG11, associated with the late manifes-
tation of severe axonal neuropathy. A similar presentation
was found in a second, unrelated Cypriot family.
Methods
In family F1, two sisters with complex HSP, with clinical
features as described below were investigated. Informed
consent (UCLH: N99/103) was obtained from all individ-
uals and the institutional review boards at the participating
medical centers approved the study. Acquired spastic
paraplegia was excluded and neurophysiological studies,
MRI scans and skin biopsies were performed using stan-
dard methods. Genomic DNA samples from the two
affected individuals and two unaffected relatives were used
for molecular genetic analyses (supplementary material).
The mutation in the Cypriot family was previously reported
[4].
Exome sequencing was performed as previously
described [16–18] using the Agilent SureSelect kit and run
on the Illumina HiSeq2500. Sequences were aligned with
the Burrows-Wheeler Aligner, duplicates were removed
with Picard, indels aligned and base quality scores recali-
brated with the Genome Analysis Toolkit (GATK). The
average sequencing depth was 55-fold with variants being
filtered according to pathogenicity, inheritance pattern, and
segregation in the family. We confirmed causative variant
candidates by the Sanger sequencing method using an
automatic genetic analyzer. SPG11 PCR primers were
designed using Primer3 so that the PCR products would
span whole exons and about 35 bp of flanking introns
(http://primer3.ut.ee/). Primer sequences are listed in the
supplementary file. Touchdown PCR was done using the
PCR Master Mix (Roche) and is described in more detail in
the supplementary table. PCR amplification products were
cleaned with ExoAp. The purified PCR products was split
into two and sequenced bidirectionally with the original
primers that were used to amplify the region of interest and
Big Dye Terminator Kit v.3.1 (Applied Biosystems)
[19, 20]. Conditions were as follows: 25 cycles of denat-
uration at 95 C for 10 s, annealing at 50 C for 5 s and
extension at 60 C for 4 min. Sequencing reactions were
Table 1 SPG11 variants identified with clinical details
Proband
number
Variant Variant type Ethnic
origin
Consanguinity Family
history
Age at
onset
Current
age
Gender
F1 c.3729delC, p.S1243 fs/ Compound
heterozygous#
UK No Yes 16 39 F
c.5148dupA, p.H1717 fs
F1A c.6658_6659delAT, p.M2220Dfs*27 Homozygous# Cypriot No Yes 21 42 F
F2 c.2146C[T, p.Q716* Homozygous Pakistan Yes No Child 26 F
F4 c.7000G[C, p.A2334P/c.3146-1G[C Compound
heterozygous#
Italian/
Argentina
No Yes 23 39 F
F5 c.3809T[A, p.V1270D Homozygous# Turkish Yes Yes 12 18 M
F6 c.5769delT, p.S1923Rfs*28 Homozygous# Kenya/
India/UK
Yes Yes 20 33 F
F8 c.3623C[T, p.P1208L/
c.852_856delCTTAA, p.N284Kfs*14
Compound
heterozygous#
UK No No 19 25 F
F16 c.398delG, p.C133Lfs*22 Homozygous# Iranian Yes No 17 35 F
F26 c.5399_5407delAGATinsTGGAGGAG,
p.Q1800Lfs*31
Homozygous Pakistan Yes Yes 13 33 F
SPG11 variants were labeled according to the transcript NM_025137.3 using the standard mutation nomenclature used in molecular diagnostics.
See main text for discussion on pathogenicity. Families 2, 4, 5, 6, 8, 16, and 26 [4] are added for comparison to families F1 and F1A reported
here. * Nonsense, del deletion, N/A not available, # other family members available for segregation
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cleaned using CleanSEQ SPRI beads according to the
manufacturer’s protocol (Agencourt). Sequencing was
performed using a 3730 DNA Analyzer (Applied Biosys-
tems). SPG11 mutation positions are based on NCBI ref-
erence sequences: NM_001160227, NP_001153699 (www.
ncbi.nlm.nih.gov).
RNA isolation and reverse transcriptase
Total RNA was extracted from cultured skin fibroblasts
using Direct-zolTM RNA Miniprep (Zymo Research, USA)
according to the manufacturer’s instructions and reverse
transcribed to first strand cDNA by using random primers
and Moloney murine leukemia virus (M-MLV) reverse
transcriptase (Promega Corporation, Madison, WI, USA).
The concentration and purity of RNA was determined
spectrophotometrically. PCR amplification and sequencing
of cDNA: three primer pairs were designed in flanking
exons of those of interest to amplify the coding sequence of
exons 22 and 30 of SPG11 mRNA (Supplementary mate-
rial). Sanger sequencing was performed as above.
Results
Clinical features
The proband and her sister from family F1 (II:1 and II:2;
Fig. 1) were the first and second children of healthy, non-
consanguineous parents of British descent. At ages 19 and
16 years, respectively, they presented with progressive
walking difficulties with additional features of bulbar
dysarthria, cognitive problems, limb weakness (proximal
power MRC 2/5 and distal 1/5 on examination at the age of
39 and 36, respectively), bladder dysfunction and optic
atrophy. At first in their early 20s, limb tone was increased
and reflexes were brisk with extensor plantars and no
sensory abnormalities but at the ages 39 and 36 reflexes
were absent and there was distal sensory loss to pin prick,
light touch and temperature. Their fingers were long and
tapering, palms were discolored and there was significant
limb pain. In addition to having leg oedema the feet of both
sisters had strikingly black coloration which improved with
massage (Fig. 1). Cognitive tests showed IQs of 54 for the
proband, and although only a very limited assessment was
possible in the sister due to severe motor and language
impairment in the context of complex HSP. The overall
picture was one of the global and severe cognitive
impairments, occurring at an early age with relative sparing
of visual perceptual functions and normal hearing. Pulses
were difficult to palpate with the peripheral oedema but
capillary refill was normal as was blood pressure testing.
The proband in the Cypriot SPG11 (F1AII:2) family had
similar clinical features and initially presented at the age of
21 years with a complex HSP phenotype. When this patient
was re-examined and investigated at the age of 42 years
she had low tone and absent reflexes along with likely
distal sensory abnormalities that were difficult to define
B 
F 
A 
G H 
C D 
I 
E 
J K 
Fig. 1 Photographs of the feet in SPG11 patients F1II:1 and F1II:2
(A and B) and F1AII:2 (C and D) showing peripheral oedema and
marked discolouration of the feet that reverses with massage. Figure E
are feet from a typical SPG11 patient in her mid 30s (Family 4,
Tables 1, 2). Figure F to I shows photographs of the hands in the
proband F1II:1 and F1II:2 showing generalized tapering of the fingers
and swelling of the proximal phalanx, red discolouration of the hands,
more marked in the palms. Figure J are hands from a typical SPG11
patient, Family 4. Figure K shows an x-ray of the hands (patient
F1II:1) with mild narrowing of the proximal interphalangeal joints
bilaterally (arrows) compatible with mild osteoarthritis
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with the severe cognitive features but these occurred early
in the disease. Her feet showed similar discolouration but
she did not suffer from any pain (Figs. 1, 2; Tables 1, 2)
and strikingly different to typical SPG11 patients.
Brain MRIs in both cases showed that the corpus cal-
losum was thin with periventricular white matter changes
and possible cerebellum atrophy (Fig. 3). Nerve conduc-
tion studies show a severe length-dependent axonal sen-
sory-motor polyneuropathy affecting both lower and upper
limbs. The neuropathy was compared with other typical
SPG11 cases with complex HSP and was significantly
worse (Table 2).
Genetic studies
To identify the underlying genetic cause, we applied
whole-exome sequencing (WES) on the proband (II:1), her
affected sister (II:2) and her mother (I:1). Analysis focused
on nonsynonymous, splice-site and coding indel variants
with a minor allele frequency (MAF) of \0.5 % in the
Exome Aggregation Consortium (EXaC; www.exac.broad
institute.org), Exome Variant Server (EVS; http://evs.gs.
washington.edu) and 1000 Genomes databases (1000G;
http://www.1000genomes.org). From the variants that met
these filtering criteria in the proband, a few co-segregated
under an autosomal recessive model and at least one was
present in the mother. Of these variants, only two involved
a gene associated with complex HSP, i.e., the SPG11 gene.
These variants were validated by Sanger sequencing.
Segregation analysis confirmed that both affected siblings
and their unaffected father were heterozygotes for the
SPG11 variant in exon 22, c.3729delC. Moreover, both
affected sisters and their mother were heterozygotes for the
variant in exon 30 c.5148dupA, also indicating that these
two variants were located on the different alleles (Fig. 4).
The variant in exon 22 is a one bp deletion which creates a
C 
J I 
A Control
Rostrum 
Body 
Genu 
Splenium 
D Control
H Control
B 
E F 
Abnormal 
white maer 
Atrophy 
Abnormal 
white maer 
Cerebellum 
Fig. 2 Sagittal MRI sequence; a control MRI with corpus callosum
labeling. b Proband II:1 and c case II:2 showing thinning of the
corpus callosum and cerebral atrophy. Coronal MRI sequence;
d control. e Proband II:1 and f II:2 showing generalized atrophy
with periventicular white matter abnormalities. Axial MRI sequence;
h control. i Proband II:1 and j II:2 showing periventicular white
matter abnormalities
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frameshift disrupting the sequence from codon S1243. The
new reading frame ends in a stop 6 codon positions
downstream. Similarly the variant in exon 30 is a one bp
duplication which creates a frameshift disrupting the
sequence from codon H1717. The new reading frame ends
in a stop 3 position downstream. To analyze the conse-
quence of these mutations, we isolated RNA from the
fibroblasts of the two affected sisters and their mother,
extracted RNA and carried out RT-PCR. From our data the
mutant allele is clearly present in the cDNA (Figs. 5, 6)
and likely to exist as a truncated protein, indicating that
very little RNA has been targeted for non-sense mediated
mRNA decay (Fig. 6). The Cypriot family were found to
have a homozygous c.6658_6659delAT, p.M2220Dfs*27
mutation. This is consistent with a typical SPG11 loss of
function mutation and the family originated from a small
village in Cyprus.
Discussion
In this study, we identified novel compound heterozygous
mutations in SPG11 in a complex HSP family with thin
corpus callosum and severe axonal sensory-motor
polyneuropathy as a late manifestation of the disease.
Moreover they had feet which were oedematous and
strikingly blue–black in color as a likely result of fluid
dependency and peripheral neuropathy. A recent study by
Montecchiani et al. [14] showed that SPG11 is the causa-
tive gene of a wide spectrum of clinical features, including
autosomal recessive CMT2. The severe neuropathy in our
case is consistent with neuropathy being a major feature in
some, but not all patients with SPG11 mutations and a
complex HSP phenotype as is confirmed in the Cypriot
family. An interesting aspect of the two SPG11 families
discussed here is the initial clinical presentation as complex
HSP with a later development of an axonal neuropathy
clinically and electrophysiologically. As in SPG11 asso-
ciated with complex HSP, the variants described by Mon-
tecchiani et al. [14] were scattered throughout the entire
DNA sequence, without evidence of ‘hot spots’, and 93 %
were truncating mutations. Our findings are consistent with
this and other previous studies describing mostly mutations
II:1 II:2 
c.3729delC, p.S1243fs 
c.3729delC, p.S1243fs c.3729delC, p.S1243fs 
c.5148dupA, p.H1717fs  
c.5148dupA, p.H1717fs  c.5148dupA, p.H1717fs  
Fig. 3 Pedigree of the F1
SPG11 family. Open symbols
represent unaffected individuals
and filled symbols represent
affected individuals. The
proband is indicated by an
arrow. Stars indicate individuals
whose DNA was used for whole
exome sequencing and whose
skin biopsies were used for
fibroblast studies. Sanger
sequencing chromatograms
surround the symbols and show
segregation of mutations. Black
bar encompass the sites of
interest (mutation over control
site)
c.6658_6659delAT, 
p.M2220fs 
II:1 II:2 
c.6658_6659delAT, 
p.M2220fs 
Homozygous Homozygous 
Heterozygous Heterozygous 
Fig. 4 Pedigree of F1A Cypriot SPG11 family. Open symbols
represent unaffected individuals and filled symbols represent affected
individuals. SPG11 mutation has been previously reported
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leading to the truncation of the SPG11 protein and conse-
quent loss of function mechanism [21].
In Family 1 based on our cDNA sequencing data, we
would expect the protein to be truncated and only little of
the mRNA to be targeted for non-sense mediated decay. In
our case, one of the truncated forms of the protein is
missing the Myb domain, and the other one is missing both
the Myb and the coil–coil domains whose presence may
suggest a role of Spatacsin in regulation of gene expression
[22]. In terms of pathology, sural nerve biopsy of SPG11
has previously shown loss of unmyelinated nerve fibers and
accumulation of intra-axonal pleomorphic membranous
material [23]. Also, axonal trafficking of vesicles was
demonstrated to be impaired in neurons derived from
induced pluripotent stem cells of SPG11 patients [24].
Another alteration is in the secretory pathway. The SPG11
protein Spatacsin has been shown to account for proteins
involved in the formation of lysosomes and moreover to
interact with components of the AP5 complex involved in
membrane sorting of late endosomes [25, 26].
As our understanding of the hereditary spastic paraple-
gias increases it is clear that the clinical features are very
heterogeneous and the spectrum of signs in disease genes
such as SPG11 can vary substantially. It is noteworthy for
clinicians to consider SPG11 testing in early onset complex
HSP or where there is a combination of severe neuropathy
and spasticity.
In conclusion, we provide support for the use of whole
exome sequencing as a diagnostic tool for identification of
mutations in conditions with complex and wide
1 500 1000 1500 2000 2500 
N-terminus C-terminus 
p.S1243fs p.H1717fs 
Spatacsin 
Protein 
(2443 AA) 
All mutaons lead  
to premature stop 
sites and truncated 
mRNA species. 
aa 
F1 SPG11 Mutaon 1 F1 SPG11 Mutaon 2 
1248 AA 
1718 AA 
p.M2220fs 
2247 AA 
  F1A SPG11 Mutaon 
Fig. 5 Schematic representation of the SPG11 protein and position of
known (black) and novel (red) mutations. Mutation 1 is predicted to
truncate the full length protein from 2443 amino acids (AA) to 1248
AA, mutation 2 truncates to 1718 AA and mutation 3 to 2247 AA.
Putative functional domains are depicted as rectangles, and their
positions within the amino acid sequence are indicated: the
transmembrane domain (yellow box; positions, 163–194, 200–240,
1239–1267, and 1471–1493), glycosyl hydroxylase F1 signature (pink
box; position, 482–490), leucine zipper (gray box; position, 611–632),
coil–coil domain (brown box; position, 1556–1590), and Myb domain
(green box; position 1766–1774). Arrows indicate truncating muta-
tions; dotted arrows indicate missense mutations. Aa = amino acids
I:1 
II:1 
II:2 
I:1 
II:1 
II:2 
SPG11: NM_001160227:exon 22. 
Heterozygous c.3729delC: p.S1243fs 
SPG11: NM_001160227:exon 30. 
Heterozygous c.5148InsA: p.H1717fs 
A B 
Fig. 6 A. cDNA sequencing chromatograms of the heterozygous
exon 22 SPG11 mutation in the mother (I:1 same as control sequence)
and two affected siblings (II:1 and II:2) with deletion of a C (arrows).
B. cDNA sequencing chromatograms of the heterozygous exon 30
SPG11 mutation in the mother (I:1 same as affected sequence) and
two affected siblings (II:1 and II:2) with the insertion of an A (arrow).
The mutation is clearly visible in both chromatograms and the peak
heights are the same as genomic DNA (Fig. 3)
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presentations such as HSP. Furthermore, we extend the
findings that mutations in SPG11 are the cause of a spec-
trum of clinical features including the late manifestation of
severe axonal neuropathy.
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